Revolutionizing Therapeutic Antibody
Development with Hybridoma Generation

The Powerdoma™ Hybridoma Discovery Platform facilitates high-throughput detection using diverse techniques such as ELISA, FACS, and cell-based mirrorball assays. Consistent positive results are observed across the board, both from the 384-well high-throughput screening and the conventional 96-well screening.

Figure 1 ELISA 384-well whole plate screening

Figure 2 FACS 384-well VS 96-well

ProBio provides various high-throughput functional assays via Powerdoma^TM supernatant, such as internalization assays, KD ELISA, reporter gene assays, and GPCR assays. It is feasible at a very early stage of discovery due to the earlier achievement of the monoclonal stage, which may offer a favorable solution for antibody discovery campaigns with expedited timeline, good Ab sequence diversity and better cost-effectiveness.

Case Study: TIGIT RGA Reporter Gene Assays Using Powerdoma^TM Supernatant

Utilizing hybridoma discovery technology, successful screening of mouse antibodies targeting human proteins was achieved in just 116 days, starting from mouse immunization. From a pool of 19,200 hybridoma clones, 87 cross-positive clones were obtained after examining the cross-reactivity of human and cynomolgus proteins. Of these, 79 clones demonstrated strong binding to the overexpressed cell line. 4 optimal clones were selected for sequencing and recombinant expression, ultimately yielding 3 antibodies exhibiting binding activity.

Figure 1 Flowchart of mouse antibody discovery for single-pass membrane target A

• 
• 

Figure 3. ELISA binding of recombinant supernatant

All of the evaluated monoclonal antibodies demonstrated notable cross-species activity, successfully binding with target proteins found in both human and cynomolgus monkey specimens.

Figure 4. FACS binding of recombinant supernatant

All the tested monoclonal antibodies were capable of binding effectively with cell lines expressing the human protein of interest.